▟ Vinebot intrinsic value, daily

← back

REGN Regeneron Pharmaceuticals

pharma · valued with opus medium conviction · deep-dived 2026-10-23

STRONG BUY
Intrinsic value$649.47
Price (at call)$819.09
Margin of safety -20.7%
vs market (rating basis) +31.2%

Dupixent's growth offsets Eylea's decline; the price is fair, with no clear margin of safety.

The story

Regeneron is a science-led biotech whose cash engine has shifted from Eylea, now eroding under biosimilar and Vabysmo pressure, to Dupixent, which it shares with Sanofi and which keeps expanding into new type 2 inflammation indications (COPD, CSU, others). Libtayo, Eylea HD and a deep antibody and genetics pipeline (obesity, oncology bispecifics, Factor XI) give it a long reinvestment runway. It is a mature but still-growing franchise. R&D intensity is structurally high and the Dupixent profit split caps how much margin it can expand.

Growth of about 6% reflects Dupixent and pipeline gains net of Eylea erosion, consistent with the roughly 5.6% five-year CAGR. Margin holds near the 33-37% recent range rather than the 2021-22 peak because R&D spending stays heavy. Sales-to-capital is set at 0.8, above the reported 0.47, which is inflated by cash and investments, and a 10-year horizon credits the Dupixent and antibody-platform moat.

Value drivers

Revenue growth (Y1)6.0%
Terminal growth3.0%
Forecast horizon10y
Target operating margin34.0%
Years to target margin4
Sales-to-capital0.80
Beta0.95
Failure probability2.0%
Cost of capital (WACC)9.1%
Terminal WACC9.4%

Valuation bridge

PV of explicit FCFF30.02B
PV of terminal value37.08B
Equity value66.87B
÷ shares → per share$649.47

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 16.47B 6.0% 33.7% 4.78B 1.17B 3.62B 3.31B
2 17.40B 5.7% 33.8% 5.07B 1.17B 3.90B 3.27B
3 18.33B 5.3% 33.9% 5.35B 1.16B 4.19B 3.22B
4 19.24B 5.0% 34.0% 5.64B 1.15B 4.49B 3.16B
5 20.14B 4.7% 34.0% 5.90B 1.12B 4.78B 3.08B
6 21.02B 4.3% 34.0% 6.15B 1.09B 5.06B 2.99B
7 21.86B 4.0% 34.0% 6.40B 1.05B 5.35B 2.90B
8 22.66B 3.7% 34.0% 6.63B 1.00B 5.63B 2.80B
9 23.41B 3.3% 34.0% 6.86B 944.05M 5.91B 2.69B
10 24.11B 3.0% 34.0% 7.06B 877.97M 6.18B 2.58B

Key risks

  • Faster Eylea/Eylea HD erosion from biosimilars and Vabysmo
  • Dupixent competition from oral and next-gen type 2 inflammation drugs ahead of its 2031+ LOE
  • Pipeline failures (obesity, oncology bispecifics) and IRA drug-price negotiation

Catalysts

  • Dupixent label expansions and Phase 3 readouts in obesity, Factor XI and itepekimab
  • Eylea HD prefilled syringe and dosing approvals stabilizing the ophthalmology franchise

History

DatePriceIntrinsicMoSRating
2026-10-23$819.09 $649.47 -20.7% STRONG BUY
2026-09-21$784.67 $723.41 -7.8% STRONG BUY
2026-08-19$810.24 $657.82 -18.8% STRONG BUY
2026-07-16$664.45 $643.15 -3.2% STRONG BUY
2026-06-23$618.03 $705.54 +14.2% STRONG BUY